Bibliography

Bibliography

  1. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54 Suppl 1:S204-217.
  2. Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017;2(16).
  3. Campbell MCW, Emptage L, Corapi F, et al. Amyloid beta deposits in ex vivo retinas correlate with the severity of Alzheimer’s brain pathology. Investigative Ophthalmology & Visual Science; 2017.
  4. Liu JL, Hlavka JP, Hillestad R, Mattke S. Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment. Santa Monica, CA: RAND Corporation; 2017.
  5. CDC. Diabetes Report Card 2017. In. Atlanta, GA: Centers for Disease Contol and Prevention, US Dept of Health and Human Services; 2018.
  6. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. Jama. 2015;314(10):1021-1029.
  7. Kostev K, Rathmann W. Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. Diabetologia. 2013;56(1):109-111.
  8. Klein R, Chou C, Klein BK, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the us population. Arch Ophthalmol. 2011;129.
  9. Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin G, Jr., Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care. JAMA ophthalmology. 2017;135(6):570-575.
  10. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2012;8(1):1-13.
  11. Molinuevo JL, Ayton S, Batrla R. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathologica. 2018.
  12. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology. 2010;9(1):119-128.
  13. Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. 2020.
  14. Lambertsen KL, Soares CB, Gaist D, Nielsen HH. Neurofilaments: The C-Reactive Protein of Neurology. Brain Sci. 2020;10(1).
  15. Frost S, Martins RN, Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2010;22(1):1-16.
  16. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54 Suppl 1:S204-217.
  17. Ratnayaka JA, Serpell LC, Lotery AJ. Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye (Lond). 2015;29(8):1013-1026.
  18. Morin PJ, Abraham CR, Amaratunga A, et al. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. Journal of neurochemistry. 1993;61(2):464-473.
  19. Masuzzo A, Dinet V, Cavanagh C, Mascarelli F, Krantic S. Amyloidosis in Retinal Neurodegenerative Diseases. Frontiers in neurology. 2016;7:127.
  20. Campbell MCW, Corapi F, Emptage L, et al. [P1-116]: THE RELATIONSHIP BETWEEN AMYLOID IN THE RETINA AND A BRAIN-BASED POST-MORTEM DIAGNOSIS OF ALZHEIMER's DISEASE. Alzheimer's & Dementia. 2017;13(7S_Part_5):P284-P285.
  21. Campbell MCW, Emptage L, Redekop R, et al. Amyloid Deposits Imaged in Postmortem Retinas Using Polarimetry Predict the Severity of a Postmortem Brain Based Diagnosis of Alzheimer's Disease. Alzheimer's & Dementia; 2018.
  22. Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017;2(16).
  23. Ngolab J, Donohue M, Belsha A, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1).
  24. Dumitrascu OM, Lyden PD, Torbati T, et al. Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline. Alzheimer's & dementia (Amsterdam, Netherlands). 2020;12(1):e12109.
  25. Kile S, Au W, Parise C, et al. Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment. Am J Alzheimers Dis Other Demen. 2020;35:1533317519899800.
  26. Liu J, Itagaki Y, Ben-Shabat S, Nakanishi K, Sparrow JR. The biosynthesis of A2E, a fluorophore of aging retina, involves the formation of the precursor, A2-PE, in the photoreceptor outer segment membrane. The Journal of biological chemistry. 2000;275(38):29354-29360.
  27. Chan FTS, Pinotsi D, Gabriele S, Schierle K, Kaminski CF. Structure-Specific Intrinsic Fluorescence of Protein Amyloids Used to Study their Kinetics of Aggregation. In: Vladimir N. Uversky YLL, ed. Bio-nanoimaging. London UK: Academic Press; 2014:147-155.
  28. Thal DR, Ghebremedhin E, Haass C, Schultz C. UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain. Clinical neuropathology. 2002;21(1):35-40.
  29. Lois N, Forrester JV. Fundus Autofluorescence. Philadelphia, PA: Lippincott, Williams & Wilkins; 2009.
  30. Yung M, Klufas MA, Sarraf D. Clinical applications of fundus autofluorescence in retinal disease. Int J Retina Vitreous. 2016;2:12.